Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
4th Annual RNA-Targeted Drug Discovery Summit - Digital Event - EST

4th Annual RNA-Targeted Drug Discovery Summit - Digital Event - EST

Categories

Date of beginning

Tuesday, 07 December 2021

Duration

3 days

City

Online

Contact

Katie Jacobs

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

As the first small-molecule drug targeting RNA gains momentum, the ability to design small molecules capable of interacting with and modulating RNA is opening as a new avenue to target challenging disease pathways that have previously been considered undruggable. The 4th RNA-Targeted Drug Discovery Summit is returning once again this December, to reunite the largest community of thought leaders and experts in biology, chemistry and RNA therapeutics to discuss cutting-edge small molecule strategies capable of interacting with and modulating RNA with improved specificity, selectivity and drug-like properties. Join the leading RNA small molecule forum alongside 150+ biopharmaceutical Directors, VPs and C-Level Executives to hear the latest pioneering case studies and successfully translate your discovery and pre-clinical strategies into robust pipelines of RNA-targeted small molecule drugs that realize the full potential of this up-and-coming field. Can't join us in Boston? We have virtual attendance options available. Our custom-built virtual event platform will combine best-in-class access to the live event with live Q&A, networking opportunities, and the ability to engage with our event partners. Date and Time: December 07, 2021 at 8:30 am to December 09, 2021 at 5:00 pm Prices: Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day) - Physical: USD 4496.00,Drug Developer Pricing - 2 Day Pass (Conference Only) - Physical: USD 2999.00,Drug Developer Pricing - 3 Day Pass (Conference + Workshop Day) - Virtual: USD 3396.00,Drug Developer Pricing - 2 Day Pass (Conference Only) - Virtual: USD 2199.00,Standard Pricing - 3 Day Pass (Conference + Workshop Day) - Physical: USD 5396.00,Standard Pricing - 2 Day Pass (Conference Only) - Physical: USD 3599.00,Academic and Research Institute Pricing - 3 Day Pass (Conference + Workshop Day) - Physical: USD 3796.00,Academic and Research Institute Pricing - 2 Day Pass (Conference Only) - Physical: USD 2599.00,Academic and Research Institute Pricing - 3 Day Pass (Conference + Workshop Day) - Virtual: USD 2796.00,Academic and Research Institute Pricing - 2 Day Pass (Conference Only) - Virtual: USD 1899.00 URLs: Tickets: https://go.evvnt.com/851095-2?pid=5569 Brochure: https://go.evvnt.com/851095-3?pid=5569 Speakers: Hashim Al-Hashimi, Professor, Duke University, Matthew Disney, Professor, Scripps Research, Jennifer Petter, Founder and Chief Innovation Officer, Arrakis Therapeutics, Isaac Kimsey, Vice President Drug Discovery, Nymirum, Valerie Cullen, Senior Vice president, Research, Expansion Therapeutics, Anuradha Bhattacharyya, Executive Director Biology and NRD, PTC Therapeutics, Iris Alroy, Vice President, R&D, Yochi Slonim, Co-Founder and CEO, Anima Biotech, Razvan Nutiu, Head Life Science Technologies, Bayer, Amanda Garner, Associate Professor, University of Michigan, Oliver Rausch, Chief Scientific Officer, Storm Therapeutics, Anthony Mustoe, Assistant Professor, Baylor College of Medicine, George Calin, Professor, MD Anderson Cancer Center, Ann Boriack-Sjodin, Vice President, Molecular Discovery, Accent Therapeutics, Rabia Khan, Founder and CEO, Ladder Therapeutics, Ratni Hasane, Distinguished Scientist, F. Hoffmann-La Roche, John Schneekloth, Senior Investigator, National Cancer Institute, Aaron Frank, Assistant Professor of Biophysics, University of Michigan, Elena Menichelli, Principal Scientist II, Genomics Institute of the Novartis Research Foundation, Andrew Krueger, Principal Scientist II, Novartis Institutes for Biomedical Research, Connie Wu, Principal Scientist II, Novartis Institutes for Biomedical Research, Byron Andrews, Principal Scientist, RNA Analytics, Storm Therapeutics, Malin Lemurell, Executive Director and Head of Medicinal Chemistry, AstraZeneca, Michael White, Chief Scientific Officer, Biosplice Therapeutics, Peter Smith, Chief Scientific Officer, Remix Therapeutics, Yang Zheng, Head of Business Development, Nymirum, Richard Gregory, Professor, Harvard Medical School, Co- Director, HMS Initiative for RNA Medicine, Wah Chiu, Wallenberg - Bienenstock Professor and Professor of Bioengineering, Microbiology and Immunology, Stanford University, Satya Kuchimanchi, Vice President, CMC, Triplet Therapeutics, Beth Shafer, Head of Neuroscience, Drug Discovery Sciences, and Externalization Business Development, Takeda Pharmaceuticals International Co.